Avutometinib

Tempus AI and Verastem Oncology have announced a collaboration to develop a companion diagnostic test for the recently FDA-approved combination therapy of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

Dana-Farber Cancer Institute researchers are presenting multiple groundbreaking studies on head and neck, breast, and lung cancers at the 2025 AACR Annual Meeting in Chicago from April 25-30.

Researchers have identified a promising combination therapy using FAK inhibitors with RAF-MEK clamps that effectively overcomes treatment resistance in BRAF V600E-mutated melanoma.

Verastem Oncology will present additional analyses from the Phase 2 RAMP 201 trial evaluating avutometinib plus defactinib in recurrent low-grade serous ovarian cancer at SGO 2025, building on their FDA Priority Review submission.

Verastem Oncology secured a new credit facility of up to $150 million and a $7.5 million equity investment with Oberland Capital, refinancing existing debt with Oxford Finance.